The Path Toward Drug Value Definition: Implications of Value Initiatives in Oncology - Archive
As prices for cancer therapies continue to rise, the value offered by treatments is coming under increased scrutiny. Provider professional organizations are responding by creating value frameworks and assessments. Building on its gold-standard NCCN Guidelines®, NCCN recently released NCCN Evidence Blocks™, which provides a graphical representation of efficacy, safety, evidence quality, evidence consistency and affordability measures to allow for easy and efficient comparisons of multiple therapies. ASCO’s Value Framework, released in August, accounts for safety and efficacy measurements and offers bonus points for products that have a positive impact on cancer-related symptoms and treatment-free intervals, drug acquisition costs and patient costs.
In this webinar “The Path toward Drug Value Definition: Implications of Value Initiatives in Oncology,” Kantar Health examines the awareness, knowledge and use of value assessment tools created by professional organizations from the oncologist, manufacturer and payer perspectives. This analysis is based on quantitative and qualitative research with payers, oncologists and manufacturers. The webinar explores:
- How will payers, providers and manufacturers use these tools?
- What are opportunities and challenges associated with the implementation of these frameworks?
- What impact might they have on treatment and coverage decision making?
- What actions can a manufacturer undertake to better address the evidence needs for these value frameworks?
Kantar Health is joined by Michael Kolodziej, M.D. and Lee S. Schwartzberg, MD, FACP to discuss these questions and the implications of professional organizations’ value-based initiatives.Watch the Webinar
National Solutions, Office of the Chief Medical Officer
Chief, Division of Hematology Oncology
The University of Tennessee Health Science Center